A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)
Latest Information Update: 21 May 2022
At a glance
- Drugs Nibrozetone (Primary) ; Irinotecan
- Indications Cholangiocarcinoma; Colon cancer; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms PAYLOAD
- Sponsors EpicentRx
- 12 May 2022 Status changed from active, no longer recruiting to discontinued.
- 21 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 31 May 2020 Results (n=12) presented at the 56th Annual Meeting of the American Society of Clinical Oncology